Results from immunohistochemistry (IHC) staining with clinical CRC samples showed that galectin-8 expression is downregulated during CRC tumor progression, with a significant difference between stages T1 and T4 (Supplementary Fig. S1B and Fig. 1A). This evidence concerns the gene LGALS8 and colorectal carcinoma.